Background
Neurotoxicity, CIPN, Cancer
ADVERSE EVENT, BREAST CANCER, ADVERSE EFFECT, ONCOLOGY, CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, CANCER
Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of taxane-based treatments that affects up to 60% of patients undergoing chemotherapy [To achieve this, we considered preventive methods with no more than “moderate harm” whose “strength of recommendation” was not “against” in ASCO guidelines, and “grades of recommendation” was not “D” or “E” in the European Society for Medical Oncology (ESMO) guidelines. In ASCO guidelines, the “strength of recommendation” for all preventive medications, except ganglioside-monosialic acid (GM)-1, is “moderate or strong against” [Nevertheless, because preventive interventions should ideally be readily available, cost-effective, and have high patient adherence, we consider that surgical gloves offer a potential solution that is both practical and cost-effective (approximately $0.6 per pair). Therefore, this study aimed to examine the impact of wearing normal-sized surgical gloves on CIPN prevention to confirm the findings of a previous study that reported no difference in efficacy between small and normal-sized gloves [Furthermore, we also aim to establish whether compression therapy using two normal-sized surgical gloves in patients receiving paclitaxel treatment could decrease the incidence of CIPN, by comparing the results from the Functional Assessment of Cancer Therapy—Neurotoxicity (FACT-NTX) component questionnaire before and after neoadjuvant/adjuvant chemotherapy with paclitaxel in patients with breast cancer. Lastly, this study will investigate changes in the FACT-Taxane and National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) grade for CIPN after 6 months of chemotherapy.